Epidermal growth factor (EGF) is a potent mitogen which is continuously secreted into the gut lumen. The sequence and structure of EGF and its receptor have been known for many years. In addition, numerous studies have been performed which are starting to unravel the events which occur after EGF meets its receptor. Despite the great number of papers that have been published in this field, the physiological role of luminal EGF is still unclear. Why is this? In this article we discuss the various methods which have been used to examine the function of EGF in vitro and in vivo and discuss the limitations of these approaches. We also discuss the potential value of EGF as a therapeutic target for the treatment of human gastrointestinal disease.
Background to EGF and its receptor EGF is a 53 amino acid peptide (MW 6400) which is secreted into the gut lumen by the salivary glands, Brunner's glands of the duodenum, and also by the ulcer associated cell lineage (UACL) -a recently identified glandular structure induced at sites of injury.1 2 Its concentration in gastric juice is about 500 ng/l, while urine concentrations are about one tenth of this.3 4 Studies in which EGF has been administered intraluminally initially seem to be the most appropriate. Most of these have been performed using rats, and there is a consensus developing that luminal EGF is active in stimulating gut growth in the neonatal rat and also in the damaged bowel. Whether administration of luminal EGF to the undamaged bowel stimulates growth, however, is uncertain. The reasons for the apparently conflicting results are unclear but differences in dosage used, species studied, and bolus versus continuous infusion of EGF may all be important. Equivalent studies in humans have not been performed. When interpreting the results of studies examining the effect of luminally administered EGF, it is important that the details of the experimental protocol are considered. For example, studies examining the effect of luminal EGF on intestinal growth in intestine that has recently undergone resection may be influenced by the increased gut permeability caused by surgical handling and the presence of an anastomosis. Caution has to be shown in interpreting these results in terms of 'normal' physiology.
The importance of considering the experimental design is shown by our studies on the stability of growth factors in the gastrointestinal lumen. We have shown that luminal EGF is susceptible to proteolytic digestion in the stomach (by pepsin) but that this is reduced considerably if the pH is raised above 4.3 Protocols involving administration of acid suppressants may therefore result in an appreciable change in luminal EGF bioactivity.
Differences in the diet of the animals may also be important as we have shown that EGF is also susceptible to degradation by pancreatic proteases present in the small intestine.6 Luminal EGF is rapidly destroyed in the small intestine of fasted, but not fed, rats. This is probably because the food proteins (in the fed rats) act as competitive substrates for the luminal proteases and the digestion Leading articles express the views of the author and not those of the editor and the editorial board.
of luminal EGF is therefore decreased. Concentrations of endogenous and exogenously administered EGF will therefore vary according to whether the animals are fasted or fed and the type of diet used. We reported that systemic, but not luminal EGF, was trophic to the intestine of parenterally fed rats7 and this is often quoted as a key paper showing the lack of effect of luminal EGF. However, we have subsequently shown that the intraluminally infused EGF was rapidly digested by residual proteases and was therefore not available to stimulate growth. We 15 However, to complicate matters further, Li and co-workers have reported that removal of salivary glands does not cause intestinal atrophy but, somewhat confusingly, that artificially induced salivary hypersecretion stimulates small intestinal growth. 15 In contrast to the relatively small effect that sialadenectomy has on the non-damaged bowel, there is a general consensus that artificially-induced ulcers are more extensive and take longer to heal in rats which have undergone sialadenectomy (for example, ref13). Caution is needed before extrapolating these results to humans, although patients with gastric ulceration do have reduced levels of gastric juice EGF.16 PRODUCTION Possible clinical value of recombinant EGF Taken together, the studies performed so far suggest that the major role of EGF is to stimulate repair at sites of injury and that it plays a relatively minor role in the maintenance of normal gut growth in the human adult. However, administration of recombinant EGF via the lumen may be clinically useful for the treatment of gastrointestinal ulceration distal to the duodenum. Acid suppressants and Helicobacterpylori eradication therapy are very effective treatments for peptic ulceration. However, the treatment of inflammatory bowel disease, chemotherapy induced mucositis, and necrotising enterocolitis is still suboptimal. Preliminary studies suggest that recombinant EGF may be useful in the treatment of all these conditions.21 Although nearly all studies have examined the effect of systemic EGF on these conditions, treatment with luminal EGF may well provide a safer alternative as the bowel is damaged (with increased permeability) and luminal EGF is therefore likely to reach its receptor. If clinical trials examining the potential value of luminal EGF are to be performed, co-administration of acid suppressants (to reduce gastric digestion), protease inhibitors (to reduce proteolysis by pancreatic proteases), or trefoil peptides (which act synergistically with EGF in the healing process,22 may well improve its clinical effectiveness.
Conclusions
The jury is still out on the role of luminal EGF in the normal gastrointestinal tract. Recent evidence, however, suggests that its major function is to act as a 'luminal surveillance' peptide,23 which is available to stimulate repair and that it is not of major importance in maintaining normal gut growth. Recombinant EGF administered via the gut lumen could still prove a valuable tool for the treatment of gastrointestinal ulceration. Perhaps the old term for EGF, 'epidermal healing factor' or EHF, was more appropriate after all!
